site map  |   search  |   cases  |   home  
 
Murdock Goldenberg Schneider & Groh LPA
35 East Seventh Street, Suite 600
Cincinnati, Ohio 45202
513.345.8291 (phone)
513.345.8294 (fax)
info@mgsglaw.com




Ortho Evra Birth Control Patch
Murdock Goldenberg Schneider & Groh is investigating reports of serious health effects linked to the use of Ortho Evra Birth Control Patch. The Ortho Evra Birth Control Patch is manufactured by Ortho-McNeill Pharmaceuticals, which is a subsidiary of Johnson & Johnson. On November 10, 2005, the U.S. Food & Drug Administration declared that the patch must include a new label indicating that women who use the patch are exposed to 60% more estrogen than those who use oral birth control pills. The Food & Drug Administration has received at least 21 reports of life-threatening strokes, heart attacks, pulmonary embolisms, deep vein thrombosis, and even death associated with Ortho Evra Birth Control Patch use. The original product label for the patch indicated that its health risks were similar to those for oral contraceptives.

If you or someone close to you has suffered one of the serious health effects listed above, please click here, send us an email at info@mgsglaw.com, or call Murdock Goldenberg Schneider & Groh at (513) 345-8291. All information will be kept confidential.


Medtronic Defibrillator Wire Leads
Murdock Goldenberg Schneider & Groh, LPA is currently investigating the circumstances surrounding the defective defibrillator leads manufactured by Medtronic Inc. These leads are thin insulated wires that connect to a defibrillator. The leads carry electric impulses to the heart. Some of these leads have fractured resulting in repetitive substantial electrical shocks.

On October 15, 2007, in response to at least five reported patient deaths associated with these defibrillator leads, Medtronic issued a recall of the product. The recalled leads have been implanted in over 200,000 patients since 2004.

If you or someone close to you has suffered one of the serious health effects listed above, please click here, send us an email at info@mgsglaw.com, or call Murdock Goldenberg Schneider & Groh at (513) 345-8291. All information will be kept confidential.


Trasylol Investigation
On November 5, 2007, the U.S. Food and Drug Administration announced that Bayer Pharmaceuticals, Inc. has agreed to suspend its marketing of Trasylol, pending a detailed review of preliminary results from a Canadian study that suggested an increased risk of health complications. Trasylol is a drug that has been widely used during surgical procedures to control bleeding. Some studies have shown that serious side effects can occur as the result of Trasylol, including heart attacks, strokes, kidney failure, and anaphylactic shock - an allergic reaction which can be fatal.

If you or someone close to you has suffered one of the serious health effects listed above, please click here, send us an email at info@mgsglaw.com, or call Murdock Goldenberg Schneider & Groh at (513) 345-8291. All information will be kept confidential.

[ return to top ]


Disclaimer: The materials and content provided at or through this Web site are for general informational purposes only and should not be relied on or considered as legal advice. If you seek legal advice or representation by Murdock Goldenberg Schneider & Groh, LPA, you must first enter into a formal agreement.

Transmission of the information contained or available through this web site is not intended to create, and receipt does not constitute, an attorney-client relationship. Recipients of this information, including Internet subscribers and online readers, should not act upon this information without seeking professional counsel.


 
Copyright 2006 Murdock, Goldenberg, Schneider & Groh LPA
legal disclaimer
site design and development by matschca design, inc.